Comparative Pharmacology
Head-to-head clinical analysis: GVS versus NEOMYCIN SULFATE DEXAMETHASONE SODIUM PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus NEOMYCIN SULFATE DEXAMETHASONE SODIUM PHOSPHATE.
GVS vs NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. Dexamethasone is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby suppressing prostaglandin and leukotriene synthesis, reducing inflammation.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
Ophthalmic: 1-2 drops of the solution or small amount of the ointment (approximately 1/2 inch into the conjunctival sac) every 3-4 hours, or more frequently if needed. Otic: 4 drops into the affected ear 3-4 times daily.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Neomycin: terminal half-life ~2-3 hours after oral absorption (negligible systemic absorption); in renal impairment, half-life can extend to 12-24 hours. Dexamethasone: terminal half-life ~36-54 hours (mean ~48 hours) in adults.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Neomycin is primarily excreted unchanged in feces (~97%) after oral administration, with about 1% absorbed and renally excreted. Dexamethasone is metabolized in liver and excreted renally (~65% as metabolites, 2-5% unchanged) and in feces (~20%).
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic